Data have shown that an AFP decrease is a good prognostic surrogate in patients with HCC after radiofrequency ablation [21] or sorafenib treatment [22], whereas an early increase in AFP predicted unfavorable clinical outcomes in patients with advanced HCC treated with sorafenib [23]. Here, AFP is linked to hepatocellular carcinoma.